Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma

Immune profiling in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM) provides the framework for developing novel immunotherapeutic strategies. Here, we demonstrate decreased CD4+ Th cells, increased Treg and G-type...

Full description

Bibliographic Details
Main Authors: Accardi, F. (Author), Anderson, K.C (Author), Bae, J. (Author), Hideshima, T. (Author), Munshi, N.C (Author), Prabhala, R. (Author), Richardson, P.G (Author), Rowell, S. (Author), Shambley, A. (Author), Tai, Y.-T (Author), Wen, K. (Author)
Format: Article
Language:English
Published: Springer Nature 2022
Subjects:
Antigens, CD
apoptosis
Apoptosis
Blood Proteins
case control study
Case-Control Studies
CD223 antigen
cell proliferation
Cell Proliferation
chemistry
cytotoxic T lymphocyte
follow up
Follow-Up Studies
galectin
Galectins
human
Humans
immunology
Immunosuppression Therapy
leukocyte antigen
Leukocytes, Mononuclear
LGALS3 protein, human
lymphocyte activation
Lymphocyte Activation
metabolism
Monoclonal Gammopathy of Undetermined Significance
monoclonal immunoglobulinemia
mononuclear cell
multiple myeloma
Multiple Myeloma
pathology
plasma protein
procedures
prognosis
Prognosis
T-Lymphocytes, Cytotoxic
tumor cell culture
Tumor Cells, Cultured
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items